Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 1 (January)

1. Effect of axial length on laser spot size during photodynamic therapy: an experimental study in monkeys.
   Am J Ophthalmol, 141(1): 214-5. [Abstract] [Full-text]
2. Retinal ischemia with neovascularization in cisplatin related retinal toxicity.
   Am J Ophthalmol, 141(1): 196-7. [Abstract] [Full-text]
3. Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis.
   Am J Ophthalmol, 141(1): 123-8. [Abstract] [Full-text]
4. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study.
   Am J Ophthalmol, 141(1): 79-87. [Abstract] [Full-text]
5. Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.
   Am J Ophthalmol, 141(1): 54-61. [Abstract] [Full-text]
6. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.
   Am J Ophthalmol, 141(1): 44-53. [Abstract] [Full-text]
7. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
   Lancet Oncol, 7(1): 43-51. [Abstract] [Full-text]
8. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
   Am J Ophthalmol, 141(1): S28-33. [Abstract] [Full-text]
9. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
   Ophthalmology, 113(1): 3-13. [Abstract] [Full-text]
10. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Ophthalmology, 113(1): 14-22. [Abstract] [Full-text]
11. Messenger molecules and cell death: therapeutic implications.
    JAMA, 295(1): 81-9. [Abstract] [Full-text]
12. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Climacteric, 8(4): 342-51. [Abstract] [Full-text]
13. Current patient perceptions on the menopause: a South African perspective.
    Climacteric, 8(4): 327-32. [Abstract] [Full-text]
14. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Climacteric, 8(4): 317-26. [Abstract] [Full-text]
15. IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy.
    Climacteric, 8(4): 311-6. [Abstract] [Full-text]
16. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Climacteric, 8(4): 307-10. [Abstract] [Full-text]
17. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    N Engl J Med, 354(1): 34-43. [Abstract] [Full-text]
18. Hormone replacement therapy, body mass index and asthma in perimenopausal women: a cross sectional survey.
    Thorax, 61(1): 34-40. [Abstract] [Full-text]
19. Scientific evidence changes prescribing practice--a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003.
    BJOG, 113(1): 15-20. [Abstract] [Full-text]
20. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis.
    BJOG, 113(1): 5-14. [Abstract] [Full-text]
21. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Prostate, 66(3): 305-16. [Abstract] [Full-text]
22. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Blood, 107(2): 752-9. [Abstract] [Full-text]
23. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
    Leuk Res, 30(3): 349-53. [Abstract] [Full-text]
24. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.
    Br J Cancer, 94(1): 136-41. [Abstract] [Full-text]
25. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
    Br J Cancer, 94(1): 69-73. [Abstract] [Full-text]
26. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
    Br J Cancer, 94(1): 62-8. [Abstract] [Full-text]
27. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
    Br J Cancer, 94(1): 55-61. [Abstract] [Full-text]
28. A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.
    Br J Cancer, 94(1): 79-84. [Abstract] [Full-text]
29. Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer.
    Br J Cancer, 94(1): 18-21. [Abstract] [Full-text]
30. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.
    Br J Cancer, 94(1): 74-8. [Abstract] [Full-text]
31. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
    Cancer Chemother Pharmacol, 57(4): 436-42. [Abstract] [Full-text]
32. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    J Urol, 175(2): 533-6. [Abstract] [Full-text]
33. Discontinuation of postmenopausal hormone therapy.
    Am J Med, 118(12): 163-5. [Abstract] [Full-text]
34. The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms.
    Am J Med, 118(12): 155-62. [Abstract] [Full-text]
35. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy?
    Am J Med, 118(12): 148-54. [Abstract] [Full-text]
36. Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity.
    Am J Med, 118(12): 142-7. [Abstract] [Full-text]
37. Bilateral oophorectomy and premature menopause.
    Am J Med, 118(12): 131-5. [Abstract] [Full-text]
38. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
    Am J Med, 118(12): 88-92. [Abstract] [Full-text]
39. Estrogen with and without progestin: benefits and risks of short-term use.
    Am J Med, 118(12): 79-87. [Abstract] [Full-text]
40. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage.
    Am J Med, 118(12): 74-8. [Abstract] [Full-text]
41. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
    Am J Med, 118(12): 64-73. [Abstract] [Full-text]
42. Pulse-spray pharmacomechanical thrombolysis for proximal deep vein thrombosis.
    Eur J Vasc Endovasc Surg, 31(2): 204-11. [Abstract] [Full-text]
43. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound.
    Biochem Biophys Res Commun, 340(4): 1085-90. [Abstract] [Full-text]
44. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    N Engl J Med, 354(3): 251-60. [Abstract] [Full-text]
45. Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
    N Engl J Med, 354(3): 241-50. [Abstract] [Full-text]
46. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
    J Clin Oncol, 24(3): 491-9. [Abstract] [Full-text]
47. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
    J Clin Oncol, 24(3): 467-75. [Abstract] [Full-text]
48. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    J Clin Oncol, 24(3): 419-30. [Abstract] [Full-text]
49. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    J Clin Oncol, 24(3): 401-6. [Abstract] [Full-text]
50. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    J Clin Oncol, 24(3): 394-400. [Abstract] [Full-text]
51. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    J Clin Oncol, 24(3): 370-8. [Abstract] [Full-text]
52. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
    J Clin Oncol, 24(3): 407-12. [Abstract] [Full-text]
53. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    J Clin Oncol, 24(3): 431-6. [Abstract] [Full-text]
54. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    J Clin Oncol, 24(3): 379-85. [Abstract] [Full-text]
55. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    J Clin Oncol, 24(3): 437-43. [Abstract] [Full-text]
56. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    J Clin Oncol, 24(3): 460-6. [Abstract] [Full-text]
57. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
    J Intern Med, 259(2): 199-208. [Abstract] [Full-text]
58. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women.
    Arterioscler Thromb Vasc Biol, 26(2): 385-91. [Abstract] [Full-text]
59. Sustained delivery of growth factors from methylidene malonate 2.1.2-based polymers.
    Biomaterials, 27(12): 2609-20. [Abstract] [Full-text]
60. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors.
    Biomaterials, 27(12): 2621-6. [Abstract] [Full-text]
61. Study of a combined percutaneous local anaesthetic and the TDS system for venepuncture.
    Anaesthesia, 61(2): 123-6. [Abstract] [Full-text]
62. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke.
    Stroke, 37(2): 556-61. [Abstract] [Full-text]
63. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.
    Stroke, 37(2): 440-6. [Abstract] [Full-text]
64. Endovascular recanalization therapy in acute ischemic stroke.
    Stroke, 37(2): 419-24. [Abstract] [Full-text]
65. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
    Stroke, 37(2): 425-9. [Abstract] [Full-text]
66. Genetic fuzzy modelling and control of bispectral index (BIS) for general intravenous anaesthesia.
    Med Eng Phys, 28(2): 134-48. [Abstract] [Full-text]
67. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
    J Surg Oncol, 93(2): 145-50. [Abstract] [Full-text]
68. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
    Blood, 107(3): 885-91. [Abstract] [Full-text]
69. Design, synthesis and preliminary biological evaluations of novel amphiphilic drug carriers.
    Bioorg Med Chem Lett, 16(5): 1111-4. [Abstract] [Full-text]
70. Age-related differences in the management and outcome of patients with acute coronary syndromes.
    Am Heart J, 151(2): 352-9. [Abstract] [Full-text]
71. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
    Am Heart J, 151(2): 338-44. [Abstract] [Full-text]
72. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.
    Am Heart J, 151(2): 316-22. [Abstract] [Full-text]
73. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
    BMC Cancer, 6: 3. [Abstract] [Full-text]
74. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
    J Clin Oncol, 24(4): 681-7. [Abstract] [Full-text]
75. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    J Clin Oncol, 24(4): 675-80. [Abstract] [Full-text]
76. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    J Clin Oncol, 24(4): 668-74. [Abstract] [Full-text]
77. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    J Clin Oncol, 24(4): 663-7. [Abstract] [Full-text]
78. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
    J Clin Oncol, 24(4): 650-5. [Abstract] [Full-text]
79. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    J Clin Oncol, 24(4): 619-25. [Abstract] [Full-text]
80. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
    J Clin Oncol, 24(4): 605-11. [Abstract] [Full-text]
81. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol, 24(4): 587-92. [Abstract] [Full-text]
82. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    J Clin Oncol, 24(4): 579-86. [Abstract] [Full-text]
83. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
    J Clin Oncol, 24(4): 571-8. [Abstract] [Full-text]
84. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
    J Clin Oncol, 24(4): 593-8. [Abstract] [Full-text]
85. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.
    Expert Rev Anticancer Ther, 6(2): 281-91. [Abstract] [Full-text]
86. Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?
    Expert Rev Anticancer Ther, 6(2): 165-73. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.